Who is sponsoring NCT06773351?

NCT06773351 is sponsored by Feng Gao.

What drugs are being tested in NCT06773351?

Interventions in NCT06773351: Sevoflurane 0 + different doses of ciprofol, Sevoflurane 0.7% + different doses of ciprofol, Sevoflurane 1.0% + different doses of ciprofol 0.05, Sevoflurane 1.5% + differnet doses of ciprofol, Sevoflurane 2.0% + different doses of ciprofol, Sevoflurane 2.5% + different doses of ciprofol, Ciprofol 0 + different end-expiratory concentration of sevoflurane, Ciprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane, Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane, Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane, Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane, Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane.

What condition does NCT06773351 study?

NCT06773351 studies Induction of General Anesthesia.

Is NCT06773351 still recruiting?

NCT06773351 is currently not yet recruiting. Last updated 14 January 2025.

Last reviewed 2025-01-14 · How we verify

NCT06773351

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Response Surface Analysis for the Interaction Between Ciprofol and Sevoflurane

Not yet recruiting Phase 4 Last updated 14 January 2025

What this trial tests

Phase 4 trial testing Sevoflurane 0 + different doses of ciprofol in Induction of General Anesthesia in 300 participants. Not yet recruiting.

Timeline

1 February 2025

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Feng Gao
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	300
Start date	1 February 2025
Primary completion	31 December 2025
Estimated completion	31 December 2025

Drugs / interventions tested

Sevoflurane 0 + different doses of ciprofol — full drug profile →
Sevoflurane 0.7% + different doses of ciprofol — full drug profile →
Sevoflurane 1.0% + different doses of ciprofol 0.05
Sevoflurane 1.5% + differnet doses of ciprofol — full drug profile →
Sevoflurane 2.0% + different doses of ciprofol — full drug profile →
Sevoflurane 2.5% + different doses of ciprofol — full drug profile →
Ciprofol 0 + different end-expiratory concentration of sevoflurane
Ciprofol 0.05mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.1mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.2 mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.3 mg/kg + different end-expiratory concentration of sevoflurane
Ciprofol 0.4 mg/kg + different end-expiratory concentration of sevoflurane

Conditions studied

Induction of General Anesthesia — all drugs for Induction of General Anesthesia →

Sponsor

Feng Gao — full company profile →

Who can join

Adults 18 to 60, any sex, with Induction of General Anesthesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intravenous and inhalation combined anesthesia is a commonly used method for maintaining general anesthesia in clinical practice. This study aims to explore the interaction between ciprofol and sevoflurane. By employing response surface methodology, we constructed a three-dimensional pharmacodynamic interaction surface for various dose combinations of ciprofol and sevoflurane. This approach allows us to determine the nature of the interaction between the two drugs at any given level, thereby providing a ciprofol understanding of the dose-response relationship when ciprofol and sevoflurane are used in combination. This knowledge will serve as a theoretical basis for rational drug administration during surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Feng Gao trials

Trials by the same sponsor.

NCT07495969 — Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） · NA · not yet recruiting
NCT07390032 — The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion · NA · not yet recruiting
NCT06405724 — Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Sur · Phase 3 · not yet recruiting
NCT06410222 — Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation. · enrolling by invitation
NCT06232486 — Relationship Between Serum Vitamin D Levels and Postherpetic Neuralgia. · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06773351 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Feng Gao
Last refreshed: 14 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06773351.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing